ARCUTIS BIOTHERAPEUTICS, INC. Payments of Stock Issuance Costs
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Payments of Stock Issuance Costs of $10.82 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-25.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-02-25
- ARCUTIS BIOTHERAPEUTICS, INC. payments of stock issuance costs for the quarter ending 2024-03-31 was $10.82M.
- ARCUTIS BIOTHERAPEUTICS, INC. payments of stock issuance costs for the quarter ending 2022-09-30 was $10.84M.
- ARCUTIS BIOTHERAPEUTICS, INC. payments of stock issuance costs for fiscal 2024 was $10.82M, a 9227.59% increase from fiscal 2023.
- ARCUTIS BIOTHERAPEUTICS, INC. payments of stock issuance costs for fiscal 2023 was $116.00K, a 98.93% decline from fiscal 2022.
- ARCUTIS BIOTHERAPEUTICS, INC. payments of stock issuance costs for fiscal 2022 was $10.84M, a 1698.34% increase from fiscal 2021.
- ARCUTIS BIOTHERAPEUTICS, INC. payments of stock issuance costs for fiscal 2021 was $603.00K.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 12 month | Payments of Stock Issuance Costs 12 month as first filed |
|---|---|---|---|
| 2024-12-31 | $10.82M 10-K · filed 2025-02-25 | ||
| 2024-03-31 | $10.82M 10-Q · filed 2025-10-28 | ||
| 2023-12-31 | $116.00K 10-K · filed 2026-02-25 | $6.55M 10-K · filed 2024-02-27 | |
| 2022-12-31 | $10.84M 10-K · filed 2025-02-25 | ||
| 2022-09-30 | $10.84M 10-Q · filed 2023-11-03 | ||
| 2021-12-31 | $603.00K 10-K · filed 2024-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |